Xilio Therapeutics, Inc. (XLO)
XLONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$8.53
-0.0300 (-0.35%) today
At the close, Nov 10, 4:00 PM ET. After hours $8.53 –
- Market cap
- $56.13m
- P/E
- –
- EPS, last 4 quarters
- $-2.18
- Dividend yield
- –
- Day range
- $8.53 to $8.81
- 52-week range
- $6.47 to $11.75
- Average volume
- 12.5k
- Previous close
- $8.56
Earnings
next estimate $-1.05Next report Nov 12, 2026
Sep 2025
0.0%
Dec 2025
+49.4%
Mar 2026
+12.1%
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $19.07m | $13.69m | $12.65m | $18.69m |
| Gross profit | $19.07m | $13.69m | $12.65m | $18.69m |
| Operating income | -$1.93m | -$11.84m | -$14.11m | -$3.49m |
| Net income | -$16.29m | $10.36m | -$9.53m | -$6.37m |
Last four quarters: revenue $64.09m, margin -34.1%, free cash flow –
News
8 latest- Xilio Doses First Patient In XTX501 Cancer Trial; Plans 2027 Data Readout RTTNews · 5 hours ago
- Xilio Therapeutics, Inc. Q3 Loss Drops RTTNews · 9 hours ago
- Xilio Names Yariv Houvras Chief Medical Officer RTTNews · Sep 28, 2026
- Xilio Advances XTX501; FDA Clears IND For Phase 1/2 Trial RTTNews · Aug 12, 2026
- Cancer Stocks That Are Advancing the Future of Oncology CareZacks · May 18, 2026
- Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesZacks · May 12, 2026
- Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue EstimatesZacks · May 12, 2026
- Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue EstimatesZacks · May 11, 2026
The company
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- xiliotx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.